• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Carcinomas – pipeline review, h1 2013 - Reports Corner
 

Carcinomas – pipeline review, h1 2013 - Reports Corner

on

  • 258 views

Global Markets Direct's, 'Carcinomas - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for ...

Global Markets Direct's, 'Carcinomas - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Carcinomas, complete with latest updates, and special features on late-stage and discontinued projects.

https://www.reportscorner.com/reports/23246/Carcinomas-%E2%80%93-Pipeline-Review,-H1-2013/

Statistics

Views

Total Views
258
Views on SlideShare
258
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Carcinomas – pipeline review, h1 2013 - Reports Corner Carcinomas – pipeline review, h1 2013 - Reports Corner Presentation Transcript

    • RC Reports Corner Carcinomas – Pipeline Review, H1 2013
    • DescriptionDescription Reports Cornerwww.reportscorner.com Global Markets Direct's, 'Carcinomas - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Carcinomas, complete with latest updates, and special features on late-stage and discontinued projects.
    • Brief SummaryBrief Summary Reports Cornerwww.reportscorner.com Global Markets Direct's, 'Carcinomas - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Carcinomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Carcinomas. Carcinomas - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
    • Brief SummaryBrief Summary Reports Cornerwww.reportscorner.com Scope - A snapshot of the global therapeutic scenario for Carcinomas. - A review of the Carcinomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Carcinomas pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
    • Brief SummaryBrief Summary Reports Cornerwww.reportscorner.com Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Carcinomas. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Carcinomas pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    • Brief SummaryBrief Summary Reports Cornerwww.reportscorner.com - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
    • Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Carcinomas Overview 10 Therapeutics Development 11 An Overview of Pipeline Products for Carcinomas 11 Carcinomas Therapeutics under Development by Companies 13 Carcinomas Therapeutics under Investigation by Universities/Institutes 15 Late Stage Products 16 Comparative Analysis 16 Mid Clinical Stage Products 17 Comparative Analysis 17
    • Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com Early Clinical Stage Products 18 Comparative Analysis 18 Discovery and Pre-Clinical Stage Products 19 Comparative Analysis 19 Carcinomas Therapeutics – Products under Development by Companies 20 Carcinomas Therapeutics – Products under Investigation by Universities/Institutes 21 Companies Involved in Carcinomas Therapeutics Development 22 Sequella, Inc. 22 Eli Lilly and Company 23 GlaxoSmithKline plc 24 Merck & Co., Inc. 25 Takara Holdings Inc. 26 Aduro BioTech 27 Bayer AG 28 Momenta Pharmaceuticals, Inc. 29
    • Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com PCI Biotech AS 30 Nanobiotix 31 Cancer Research Technology Limited 32 Spectrum Pharmaceuticals, Inc. 33 Telormedix SA 34 Cellceutix Corporation 35 Viventia Biotechnologies Inc. 36 Lytix Biopharma AS 37 Carcinomas – Therapeutics Assessment 38 Assessment by Monotherapy Products 38 Assessment by Combination Products 39 Assessment by Route of Administration 40 Assessment by Molecule Type 42 Drug Profiles 45 cetuximab - Drug Profile 45
    • Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com Product Description 45 Mechanism of Action 45 R&D Progress 45 cixutumumab - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 ridaforolimus - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 (amphinex + bleomycin sulfate) - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58
    • Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com M-402 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 ramucirumab - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 ramucirumab - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 SQ-109 - Drug Profile 69 Product Description 69 Mechanism of Action 69
    • Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com R&D Progress 69 SPI-1620 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 imiquimod - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 oportuzumab monatox - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 Kevetrin - Drug Profile 77 Product Description 77
    • Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com Mechanism of Action 77 R&D Progress 77 HF-10 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 NPI-1342 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 MOC31-PE - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 LTX-315 - Drug Profile 83
    • Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com Product Description 83 Mechanism of Action 83 R&D Progress 83 aspirin - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 nelfinavir mesylate - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 GV-1001 + LTX-315 - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86
    • Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com bevacizumab + [cisplatin] + Radiation Therapy - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 LMP Specific Cytotoxic T-Lymphocytes - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 bevacizumab + [fluorouracil] + [leucovorin calcium] + [oxaliplatin] - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 lambrolizumab - Drug Profile 90 Product Description 90 Mechanism of Action 90
    • Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com R&D Progress 90 cidofovir - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 BAY-94-9343 - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 ANZ-100 - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 LY-2510924 - Drug Profile 95 Product Description 95
    • Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com Mechanism of Action 95 R&D Progress 95 dasatinib + [erlotinib hydrochloride] + [gemcitabine hydrochloride] - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 interleukin-15 - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 interferon alfa-2b biosimilar - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 Anti-S100A4 Monoclonal Antibody - Drug Profile 100
    • Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com Product Description 100 Mechanism of Action 100 R&D Progress 100 NBTX-IV - Drug Profile 101 Product Description 101 Mechanism of Action 101 R&D Progress 101 Platinum Based Compounds - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 PMA-104R - Drug Profile 103 Product Description 103 Mechanism of Action 103 R&D Progress 103
    • Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com Carcinomas Therapeutics – Drug Profile Updates 104 Carcinomas Therapeutics – Discontinued Products 126 Carcinomas Therapeutics - Dormant Products 127 Carcinomas – Product Development Milestones 130 Featured News & Press Releases 130 May 01, 2013: GSK Announces FDA Extension Of PDUFA Date For Trametinib By Three Months 130 Jun 29, 2012: Topotarget Announces Top-Line Results From Phase II Trial Of Belinostat For Treatment Of Cancer 130 Oct 04, 2011: Fresenius Biotech Obtains Reimbursement Approval For Removab Antibody In Belgium 131 Sep 19, 2011: Spectrum Announces Positive First Part Of Phase I Study Results Of SPI-1620 In Carcinomas 131 Jun 14, 2011: ImmunoGen Earns Milestone With BAY 94-9343 IND Submission 132 Jun 07, 2011: Fresenius Biotech Presents New Data Of Trifunctional Antibody Removab At ASCO 133 Jun 07, 2011: Fresenius Biotech Presents New Data Of Trifunctional Antibody Removab At ASCO 134 May 26, 2011: ImmunoGen Announces Clinical Presentation Of IMGN901 At ASCO 2011 Annual Meeting 135
    • Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com Apr 04, 2011: ImmunoGen Announces First Data For New Therapeutic For Ovarian Cancer And Other Carcinomas 135 Apr 04, 2011: Curis Announces Investigator-Initiated Phase II Study Results Presented At 102nd AACR Annual Meeting 2011 136 Appendix 138 Methodology 138 Coverage 138 Secondary Research 138 Primary Research 138 Expert Panel Validation 138 Contact Us 139 Disclaimer 139
    • For more informationFor more information Reports Cornerwww.reportscorner.com For more information please visit our website https://www.reportscorner.com/reports/23246/Carcinomas-%E2%80%93-Pipeline- Review,-H1-2013/
    • Reports Corner Thank YouThank You www.reportscorner.com RC Contact us: contact@reportscorner.com